An Australian clinical-stage company built on evidence.
Precision that preserves.
Our mission
ImmunoPDT exists to treat early prostate cancer while aiming to preserve the quality of life that radical treatment can take away. The goal is to give men a credible, function-preserving option grounded in long-term human data.
What ImmunoPDT is
ImmunoPDT is an Australian-developed photodynamic therapy approach for early prostate cancer, currently in Phase 2 clinical evaluation. The patient receives Immuno1, an oral photosensitising agent, which is activated within the prostate by a red-light diffuser (660 nm). It is a therapy platform that pairs an oral agent with a light-based instrument, rather than a single-compound company.
Governance posture
ImmunoPDT operates under a strict claims-governance regime. Every outcome is described as reported and attributed to its source. The therapy is investigational and not approved for marketing in any jurisdiction. Clinical leadership rests with the Principal Investigator, supported by the company's directors and clinical investigators.
Corporate structure
ImmunoPDT's technology is held under a licensed corporate structure that separates the broader platform rights from the prostate-specific operating company. The patent estate covers the agent class and the activation protocol.
Hudson Institute
Hudson Institute supports the scientific programme behind ImmunoPDT.
National Institute of Integrative Medicine (NIIM)
NIIM hosts and supports the Phase 2 clinical programme.
About ImmunoPDT, ImmunoPDT is an Australian clinical-stage company developing a function-preserving photodynamic therapy for early prostate cancer. Its agent, Immuno1, is activated by targeted 660 nm red light within the prostate and is designed to destroy the tumour locally and to activate a local immune response. The programme has long-term Phase 1 human follow-up and an active Phase 2 in Australia. Immuno1 is investigational and not approved for marketing in any jurisdiction.